Monalizumab (Anti-Human CD159a)

製品コード：A2053         Batch: A205301

印刷

Monalizumab (Anti-Human CD159a) is a novel, first-in-class humanized immunoglobulin G4 monoclonal antibody immune checkpoint inhibitor that targets the inhibitory CD94/NKG2A receptors.

製品説明

CAS No. 1228763-95-8
Formulation PBS Buffer, PH 7.4
Isotype Human IgG4-Kappa
Application Monalizumab (Anti-Human CD159a)
Storage
(From the date of receipt)		 Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles
Shipping Shipped under low temperature conditions
Purity 99%
Protein concentration 10.72mg/ml
Endotoxin Level ＜1EU/mg

カスタマーフィードバック

A2053-Monalizumab-Anti-Human-CD159a.gif

Selleckの高級品が、幾つかの出版された研究調査結果（以下を含む）で使われた：

Orchestrating T and NK cells for tumor immunotherapy via NKG2A-targeted delivery of a de novo designed IL-2Rβγ agonist [ Drug Deliv, 2025, 32(1):2482195] PubMed: 40170468

人間や獣医の診断であるか治療的な使用のためにでない。